(Q39029380)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918214%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

review article

1 reference

title

Immunosuppression and adult heart transplantation: emerging therapies and opportunities (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918214%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918214%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Nicholas Furiasse

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918214%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

language of work or name

1 reference

14 December 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918214%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Cardiovascular Therapy

29 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918214%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918214%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918214%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

page(s)

59-69

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918214%20AND%20SRC:MED&resulttype=core&format=json

Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association

29 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Long-term use of a left ventricular assist device for end-stage heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Seventh INTERMACS annual report: 15,000 patients and counting

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Heart Transplantation Report--2015; Focus Theme: Early Graft Failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Regulatory immune cells in transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Evaluation of the highly sensitized transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Mechanisms of rejection: current perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Calculated PRA (CPRA): the new measure of sensitization for transplant candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Utility of virtual crossmatch in sensitized patients awaiting heart transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Mechanisms and role of HLA and non-HLA alloantibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Desensitization strategies in adult heart transplantation-Will persistence pay off?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Report from a consensus conference on the sensitized patient awaiting heart transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

To induce or not to induce: do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Alemtuzumab (Campath-1H): a systematic review in organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

The efficacy and safety of alemtuzumab and daclizumab versus antithymocyte globulin during organ transplantation: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Daclizumab to prevent rejection after cardiac transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Immunosuppressive T-cell antibody induction for heart transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

A prospective, randomized trial of single-drug versus dual-drug immunosuppression in heart transplantation: the tacrolimus in combination, tacrolimus alone compared (TICTAC) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Pre- and posttransplantation allosensitization in heart allograft recipients: Major impact of de novo alloantibody production on allograft survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Current and future challenges in therapy for antibody-mediated rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Plasmapheresis and cyclophosphamide in the treatment of humoral rejection after heart transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Antibody-directed therapy: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Update on extracorporeal photopheresis in heart and lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Reduction of alloantibodies via proteasome inhibition in cardiac transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Presentation and Outcomes of C4d-Negative Antibody-Mediated Rejection After Kidney Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Effect of pravastatin on outcomes after cardiac transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Immunosuppression for heart transplantation: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

New insights into the regulation of T cells by gamma(c) family cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Monoclonal anti-interleukin-6 receptor antibody attenuates donor-specific antibody responses in a mouse model of allosensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

A Phase I/II Trial of the Interleukin-6 Receptor-Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunoglobulin in Difficult to Desensitize Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Proteolytic processing of the streptococcal IgG endopeptidase IdeS modulates the functional properties of the enzyme and results in reduced immunorecognition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Gene-expression profiling for rejection surveillance after cardiac transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Randomized pilot trial of gene expression profiling versus heart biopsy in the first year after heart transplant: early invasive monitoring attenuation through gene expression trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

MicroRNA profiling: approaches and considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: durable chimerism predicts outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

Predicting acute cardiac rejection from donor heart and pre-transplant recipient blood gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14779072.2017.1267565

10.1080/14779072.2017.1267565

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918214%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918214%20AND%20SRC:MED&resulttype=core&format=json